A large study supports the use of stereotactic radiosurgery in patients with 15 or more brain metastases, finding improved cognitive outcomes and comparable survival to whole brain radiation.
Definitive treatment to the primary site improves overall and cancer-specific survival among patients with brain-only NSCLC metastases, a recent retrospective study shows.
Investigators found no significant survival benefit after prophylactic cranial irradiation in patients with SCLC who did not have preexisting brain metastases.
In previously treated patients with locally advanced unresectable or metastatic HER2-positive breast cancer, tucatinib and trastuzumab emtansine improved progression-free survival vs T-DM1 alone.
In cancer patients with brain metastases, preoperative stereotactic radiotherapy is associated with improved outcomes compared to no SRT, a small trial shows.